Bright Minds Biosciences Inc.
CAValuation Metrics
Bright Minds Biosciences Inc.'s Market Cap is $597M. At end of 2025 it was $606M. Ranked #2724 of 3,121 in US market (top 87%), #1176 of 1,463 on NASDAQ (top 80%), #217 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $597M | US#2,724/3,121 Sec#217/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-18M | US—/3,121 Sec—/266 |
| Total Assets | $223M | US#2,979/3,121 Sec#242/266 |
| Net Assets | $222M | US#2,652/3,121 Sec#180/266 |
| Employees | 26 | US#2,763/3,121 Sec#221/266 |
| Value | ||
| P/B | 2.69x | US#1,635/3,121 Sec#79/266 |
| FCF Yield | -3.00% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -7.99% | US#2,329/3,121 Sec#77/266 |
| ROA | -7.93% | US#2,617/3,121 Sec#96/266 |
| Financial Health | ||
| Debt Ratio | 0.83% | US#8/3,121 Sec#1/266 |
| Total Debt | $47208.00 | US#3,025/3,121 Sec#262/266 |
| FCF | $-18M | US#2,411/3,121 Sec#91/266 |
| Cash | $221M | US#1,654/3,121 Sec#101/266 |
| Current Ratio | 121.97x | US#31/3,121 Sec#1/266 |
| Performance | ||
| 1Y Return | 21.60% | US#752/3,121 Sec#124/266 |
| 1M Return | -28.04% | US#3,063/3,121 Sec#258/266 |
| From 52W High | -50.72% | US#2,727/3,121 Sec#216/266 |
| 1Y MDD | -38.42% | US#1,936/3,121 Sec#132/266 |
| Trading | ||
| Volume | 134,789 shares | US#3,004/3,121 Sec#263/266 |
| Trading Value | $8M | US#2,728/3,121 Sec#231/266 |
| Per Share | ||
| EPS | $-1.81 | US—/3,121 Sec—/266 |
| BPS | $22.64 | US#1,130/3,121 Sec#24/266 |
Company Info
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.